CSS
NKTR icon

Cubist Systematic Strategies’s Nektar Therapeutics NKTR Stock Holding History

Cubist Systematic Strategies’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$233K Buy
+4,097
New +$136K ﹤0.01% 2608
2024
Q2 		– Sell
-3
Closed -$37 – 3689
2024
Q1 		$37 Sell
3
-1,584
-100% -$16.6K ﹤0.01% 3619
2023
Q4 		$13.4K Buy
1,587
+1,155
+267% +$8.75K ﹤0.01% 3377
2023
Q3 		$3.86K Sell
432
-1,132
-72% -$10.9K ﹤0.01% 3179
2023
Q2 		$13.5K Sell
1,564
-2,531
-62% -$27K ﹤0.01% 3224
2023
Q1 		$43.2K Sell
4,095
-20,318
-83% -$615K ﹤0.01% 3587
2022
Q4 		$828K Buy
24,413
+10,752
+79% +$520K ﹤0.01% 2625
2022
Q3 		$656K Sell
13,661
-3,823
-22% -$227K ﹤0.01% 2958
2022
Q2 		$997K Sell
17,484
-42,039
-71% -$2.65M 0.01% 2490
2022
Q1 		$4.81M Buy
59,523
+24,433
+70% +$3.62M 0.04% 762
2021
Q4 		$7.11M Buy
35,090
+24,970
+247% +$5.42M 0.07% 428
2021
Q3 		$2.73M Buy
10,120
+5,892
+139% +$1.42M 0.03% 814
2021
Q2 		$1.09M Sell
4,228
-2,954
-41% -$818K 0.01% 1513
2021
Q1 		$2.15M Sell
7,182
-2,666
-27% -$830K 0.03% 983
2020
Q4 		$2.51M Buy
9,848
+4,195
+74% +$1.08M 0.03% 805
2020
Q3 		$1.41M Buy
5,653
+151
+3% +$47.5K 0.02% 1130
2020
Q2 		$1.91M Buy
5,502
+3,201
+139% +$999K 0.03% 823
2020
Q1 		$616K Sell
2,301
-740
-24% -$229K 0.02% 1122
2019
Q4 		$985K Buy
3,041
+978
+47% +$284K 0.02% 1167
2019
Q3 		$564K Sell
2,063
-4,613
-69% -$1.69M 0.01% 1240
2019
Q2 		$3.56M Sell
6,676
-965
-13% -$484K 0.07% 413
2019
Q1 		$3.85M Buy
+7,641
New +$4.53M 0.12% 206
2018
Q4 		– Sell
-219
Closed -$200K – 2214
2018
Q3 		$200K Sell
219
-251
-53% -$214K 0.01% 1413
2018
Q2 		$344K Sell
470
-2,397
-84% -$2.76M 0.02% 994
2018
Q1 		$4.57M Buy
+2,867
New +$3.69M 0.27% 62
2016
Q4 		– Sell
-1,801
Closed -$464K – 1830
2016
Q3 		$464K Buy
1,801
+1,007
+127% +$259K 0.03% 750
2016
Q2 		$169K Buy
794
+662
+502% +$148K 0.01% 1392
2016
Q1 		$27K Sell
132
-2,568
-95% -$493K ﹤0.01% 1519
2015
Q4 		$682K Buy
2,700
+1,475
+120% +$303K 0.04% 663
2015
Q3 		$201K Sell
1,225
-3,497
-74% -$619K 0.01% 1478
2015
Q2 		$886K Buy
+4,722
New +$813K 0.04% 646
2015
Q1 		– Sell
-2,155
Closed -$501K – 2020
2014
Q4 		$501K Sell
2,155
-339
-14% -$72.5K 0.03% 860
2014
Q3 		$452K Buy
2,494
+332
+15% +$63.5K 0.03% 893
2014
Q2 		$416K Buy
+2,162
New +$382K 0.03% 815

Other funds holding NKTR

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cubist Systematic Strategies's NKTR Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in Nektar Therapeutics (NKTR) in Q3 2025: 4,097 shares worth $233K. The stake represents ﹤0.01% of the portfolio and ranks #2608 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in NKTR as recently as Q1 2024.

Cubist Systematic Strategies first reported a position in NKTR in Q2 2014 and has held it in 34 quarters since. The position peaked at $7.11M in Q4 2021. 154 funds tracked by Wall St. Rank hold NKTR as of Q3 2025.

  • Cubist Systematic Strategies held 4,097 shares of Nektar Therapeutics worth $233K as of Q3 2025.
  • Nektar Therapeutics was a new Cubist Systematic Strategies position in Q3 2025.
  • Nektar Therapeutics made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2608 holding.
  • Cubist Systematic Strategies first reported a position in Nektar Therapeutics in Q2 2014 and has held it in 34 quarters since.
  • Cubist Systematic Strategies's Nektar Therapeutics position peaked at $7.11M in Q4 2021.
  • 154 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.